2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Apolipoprotein

Apolipoprotein

Plasma lipoprotein metabolism is regulated and controlled by the specific apolipoprotein (apo-) constituents of the various lipoprotein classes. The major apolipoproteins include apoE, apoB, apoA-I, apoA-II, apoA-IV, apoC-I, apoC-II, and apoC-III. Specific apolipoproteins function in the regulation of lipoprotein metabolism through their involvement in the transport and redistribution of lipids among various cells and tissues, through their role as cofactors for enzymes of lipid metabolism, or through their maintenance of the structure of the lipoprotein particles.

Apolipoprotein Isoform Specific Products:

Apolipoprotein Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-RS00846
    APOC3 Human Pre-designed siRNA Set A
    		Inhibitor

    APOC3 Human Pre-designed siRNA Set A contains three designed siRNAs for APOC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    APOC3 Human Pre-designed siRNA Set A
  • HY-RS00844
    APOC1 Human Pre-designed siRNA Set A

    APOC1 Human Pre-designed siRNA Set A contains three designed siRNAs for APOC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Components

    APOC1 siRNA-1: 5 nmol (HPLC)

    APOC1 siRNA-2: 5 nmol (HPLC)

    APOC1 siRNA-3: 5 nmol (HPLC)

    siRNA Negative Control: 5 nmol (HPLC)

    FAM-labeled siRNA Negative Control: 5 nmol (HPLC)

    GAPDH siRNA Positive Control: 5 nmol (HPLC)
    APOC1 Human Pre-designed siRNA Set A
  • HY-176196
    APOL1-IN-3
    		Inhibitor
    APOL1-IN-3 (Compound 1) is an APOL1 inhibitor. APOL1-IN-3 can be used in the research of kidney diseases.
    APOL1-IN-3
  • HY-P6365A
    APL180
    APL180 (L-4F) is an apolipoprotein A-I mimic peptide, that improves the anti-inflammatory activity of high-density lipoprotein (HDL). APL180 can be used in researches of cardiovascular diseases.
    APL180
  • HY-171465
    Lp(a)-IN-6
    Lp(a)-IN-6 (Compound 6) is a lipoprotein(a) (Lp(a)) inhibitor, with an IC50 of <0.314 nM. Lp(a)-IN-6 can be used for the research of cardiovascular disease (CVD).
    Lp(a)-IN-6
  • HY-W778692
    1-Linoleoyl Glycerol-d5
    1-Linoleoyl Glycerol-d5 (1-Linoleoyl-rac-glycerol-d5; 1-Monolinolein-d5) is the deuterium labeled 1-Linoleoyl Glycerol (HY-111346). 1-Linoleoyl glycerol is a LpPLA2 inhibitor. 1-Linoleoyl glycerol acts as a precursor for synthesizing various functional lipids, such as phospholipids. 1-Linoleoyl glycerol mitigates inflammation induced by Apolipoprotein CIII (reduction of IL-6).
    1-Linoleoyl Glycerol-d<sub>5</sub>
  • HY-147425D
    FAM labled Zerlasiran sodium
    		Inhibitor
    FAM labled Zerlasiran sodium is a FAM labled Zerlasiran sodium (HY-147425A). Zerlasiran sodium is a siRNA targeting apolipoprotein A (ApoA). Zerlasiran sodium targets hepatic ApoA synthesis via RNA interference to degrade encoding mRNA. Zerlasiran sodium can be used for the research of atherosclerotic cardiovascular disease and elevated ApoA levels.
    FAM labled Zerlasiran sodium
  • HY-18778B
    Obicetrapib potassium
    		Inhibitor
    Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD).
    Obicetrapib potassium
  • HY-P5169
    LVGRQLEEFL (mouse)
    LVGRQLEEFL (mouse) can be named as G * peptide, corresponding to amino acids 113 to 122 in apolipoprotein J ([113,122] apoJ)}. LVGRQLEEFL (mouse) exhibits anti-inflammatory and anti-atherogenic properties. LVGRQLEEFL (mouse) can be added to an apoJ mimetic, to form HM-10/10 peptide, which is a mimetic peptide and a novel chimeric high density lipoprotein. HM-10/10 peptide protects retinal pigment epithelium (RPE) and photoreceptors from oxidant induced cell death.
    LVGRQLEEFL (mouse)
  • HY-169932
    APOL1-IN-2
    		Inhibitor
    APOL1-IN-2 (Compound 467) is the inhibitor for Apolipoprotein 1 (APOL1). APOL1-IN-2 reduces the APOL1 G2/G1 induced cell death in HEK293 with EC50 of 4.74 nM and 14.3 nM. APOL1-IN-2 reduces the APOL1 G2/G1/G0 induced death of trypanosomes with EC50 of 2.24, 6.03 and 3.72 nM, respectively.
    APOL1-IN-2
  • HY-13031
    GW 841819X
    		Activator
    GW 841819X is a potent inducer of the ApoA1 report gene, with an EC170 of 0.22 µM, and its pIC50 for Brd2/3/4 is 5.9/6.2/6.3.
    GW 841819X
  • HY-P991865
    Anti-ApoCIII Antibody
    Anti-ApoCIII Antibody is an antibody against human ApoCIII. Recommend Isotype Controls:?Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    Anti-ApoCIII Antibody
  • HY-169080
    ABCA1 inducer 1
    		Inducer
    ABCA1 inducer 1 is a nonlipogenic ABCA1 inducer. ABCA1 inducer 1 increases ABCA1 expression, enhances apolipoprotein (APOE) lipidation and reverses multiple Alzheimer’s disease (AD) phenotypes, without increasing triglycerides in E3/4FAD mice that express human APOE 3/4.
    ABCA1 inducer 1
  • HY-127055
    Tiadenol
    		Inhibitor
    Tiadenol is an absorbable hypolipidemic agent. Tiadenol can effectively reduce triglycerides and decrease the level of apolipoprotein E in very low-density lipoproteins in hyperlipoproteinemia. Tiadenol causes hepatomegaly in rats and affects their hepatic lipid levels, cholesterol synthesis and absorption at high doses. Tiadenol can be used in the research of endocrine and metabolic diseases such as hyperlipidemia.
    Tiadenol
  • HY-165061
    5(Z),11(Z),14(Z)-Eicosatrienoic acid
    		Inhibitor
    5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.
    5(Z),11(Z),14(Z)-Eicosatrienoic acid
  • HY-P992470
    STT-5058
    		Inhibitor
    STT-5058 (ARGX-116; NN5058) is a human monoclonal antibody targeting ApoC3 and belongs to the class of ApoC3 inhibitors. STT-5058 exhibits pH-dependent circulation properties and binds to a unique epitope on ApoC3. STT-5058 reduces triglyceride levels and accelerates the clearance of atherogenic remnant lipoproteins containing ApoC3. STT-5058 can be used in research related to hypertriglyceridemia, dyslipidemia and cardiovascular diseases.
    STT-5058
  • HY-177653
    Opemalirsen
    		Inhibitor
    Opemalirsen is an antisense oligonucleotide targeted to apolipoprotein L1 (APOL1). It is used for the study of Kidney disorders.
    Opemalirsen
  • HY-P992191
    Anti-ApoL1 Antibody
    Anti-ApoL1 Antibody is a monoclonal antibody that targets ApoL1. It can be used in ELISA, FACS, and functional assays. For isotype controls of Anti-ApoL1 Antibody, please refer to Rabbit IgG1 kappa, Isotype Control (HY-P99980).
    Anti-ApoL1 Antibody
  • HY-177653B
    Opemalirsen sodium scrambled negative control
    		Inhibitor
    Opemalirsen sodium scrambled negative control is the sequence scrambled negative control of Opemalirsen sodium.
    Opemalirsen sodium scrambled negative control
  • HY-112798S
    PH-002-d8
    PH-002-d8 is the deuterium labeled PH-002 (HY-112798). PH-002 is an inhibitor of apolipoprotein (apo) E4 intramolecular domain interaction in neuronal cells that could rescue impairments of mitochondrial motility and neurite outgrowth.
    PH-002-d<sub>8</sub>
Apolipoprotein Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.